A short review is given about some of the data reported in the literature on dehydroepiandrosterone and its derivatives, delta 5-androstenediol (hermaphrodiol) and sexual steroid binding globulin (SHBG) in breast cancer patients. The reported results lead to hypothesis that a decreased SHBG binding activity may be found in these patients.
|